To explore whether these in vitro dependencies of gastric tumor organoids could translate to therapeutic approaches in vivo, we treated tumor-bearing gp130F/F mice with α-IL13 or α-IL25 neutralizing antibodies (Fig. 5a). This evidence concerns the gene IL13 and neoplasm.